Speculative Excess on the Fringes: Leveraged ETFs Signal Shifting Fed ExpectationsGlobal Report·1 hour agoCURX-2.55%
Genmab's USD 1.2 Billion Revenue Surge Contrasts With FMC's Pivot in Tactical Market ShuffleGlobal Report·3 hours agoCURX-2.55%GMAB-2.05%
Healthcare Divergence: Curia Restructures Over USD 1B Debt as Genmab Preps Late-Stage Oncology PipelineGlobal Report·3 hours agoCURX-2.55%GMAB-2.05%
Pre-market hot trades in US stocks: PicoCELA pre-market down 10.72%; Curanex Pharmaceuticals pre-market down 10.44%Price Alert·4 hours agoPCLA+32.66%CURX-2.55%
Curanex Pharmaceuticals Inc Q2 2026: Net income $(3.29M), EPS $(0.12) — 10-Q SummaryTradingView·Aug 14 at 11:21 AMCURX-2.55%
12 Health Care Stocks Moving In Wednesday's Pre-Market Sessionbenzinga_article·Jul 29 at 07:05 AMNEO-0.75%AMIX-10.83%
12 Health Care Stocks Moving In Tuesday's Pre-Market Sessionbenzinga_article·Jun 30 at 07:05 AMUPC-0.19%DCOY-3.81%
Curanex shareholders back 1-for-10 to 1-for-50 reverse stock split to meet Nasdaq $1 bid rulePUBT·Jun 29 at 09:20 AMCURX-2.55%
Curanex Pharmaceuticals files draft information statement (Form PRE 14C)PUBT·Jun 18 at 04:12 PMCURX-2.55%
12 Health Care Stocks Moving In Tuesday's After-Market Sessionbenzinga_article·Jun 9 at 04:06 PMCNTX+6.61%PMI-7.90%
07:37 ETWolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX)prnewswire·May 18 at 06:37 AMCURX-2.55%
